What Is AOD-9604? Uses, Risks, and FDA Status
What Is AOD-9604?
AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide fragment derived from the C-terminal end of human growth hormone (amino acids 177-191). It was developed at Monash University in Australia specifically to isolate the fat-metabolizing properties of growth hormone without its growth-promoting or diabetogenic effects. AOD-9604 has been granted GRAS (Generally Recognized as Safe) status by the FDA for use as a food ingredient, which is unusual for a peptide.
How Does AOD-9604 Work?
AOD-9604 mimics the way natural growth hormone regulates fat metabolism. It stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the formation of new fat). Unlike full-length growth hormone, AOD-9604 does not affect blood sugar levels or promote tissue growth, because it only replicates the fat-specific signaling portion of the GH molecule. Research suggests it works by activating the beta-3 adrenergic receptor pathway in adipose tissue (Heffernan et al., J Endocrinol, 2001). This targeted mechanism is what makes it attractive as a body composition agent without the broader hormonal effects of GH.
What Is AOD-9604 Used For?
Based on published research, AOD-9604 has been investigated for:
- Fat loss — The primary use case; research in obese animal models showed significant reductions in body fat without affecting lean mass or IGF-1 levels
- Body composition optimization — Used in clinical settings for patients seeking fat reduction without the side effects of growth hormone therapy
- Cartilage repair — Preliminary research suggests potential benefits for osteoarthritis and cartilage regeneration (Metabolic Pharmaceuticals clinical data)
- Metabolic health — Investigated for effects on metabolic markers in overweight individuals
What Are the Risks?
- Mixed clinical trial results. While animal studies were promising, human clinical trials for obesity conducted by Metabolic Pharmaceuticals showed modest results that did not meet primary endpoints for FDA drug approval.
- Limited published human data. The human clinical trial data is largely proprietary and has not been extensively published in peer-reviewed journals.
- Injection site reactions. Mild redness, swelling, or discomfort at the injection site.
- Headaches. Some users report mild headaches, particularly during initial use.
- Uncertain efficacy at compounded doses. The doses used in clinical trials may differ from those commonly prescribed in compounding settings, making it difficult to extrapolate results.
- Not a standalone solution. AOD-9604 is not a substitute for diet and exercise; research suggests it works best as an adjunct to lifestyle modifications.
FDA Status
AOD-9604 has a unique regulatory position. It holds GRAS status from the FDA as a food ingredient (granted in 2014), which is distinct from drug approval. It was reclassified to Category 1 in February 2026 and is available through licensed compounding pharmacies with a physician prescription. It is not FDA-approved as a drug for obesity or any other indication. Its prior GRAS designation and Category 1 status give it a relatively clear compounding pathway compared to many other peptides.
Key Takeaway
AOD-9604 is a growth hormone fragment designed specifically for fat metabolism, with FDA GRAS status and Category 1 classification, though human clinical trial results for weight loss have been modest.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.